Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Apoptosis Regulatory Proteins/genetics; Depsipeptides/administration & dosage; Drug Resistance, Neoplasm/genetics; Histone Deacetylase Inhibitors/therapeutic use; Lymphoma, T-Cell, Cutaneous/drug therapy; MAP Kinase Signaling System/physiology; Membrane Proteins/genetics; Protein Kinase Inhibitors/administration & dosage; Proto-Oncogene Proteins/genetics; Apoptosis Regulatory Proteins/metabolism; Bcl-2-Like Protein 11; Clinical Trials, Phase II as Topic; Down-Regulation/drug effects; Down-Regulation/genetics; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm/physiology; Enzyme Activation/drug effects; Enzyme Activation/physiology; Gene Expression Regulation, Neoplastic/drug effects; Histone Deacetylase Inhibitors/administration & dosage; Humans; Lymphoma, T-Cell, Cutaneous/genetics; Lymphoma, T-Cell, Cutaneous/metabolism; MAP Kinase Kinase 1/antagonists & inhibitors; MAP Kinase Signaling System/drug effects; Membrane Proteins/metabolism; Oligonucleotide Array Sequence Analysis; Proto-Oncogene Proteins/metabolism; Rationalization; Transcriptome; Tumor Cells, Cultured